Illumina, Varian Among Flurry Of China Collabs

The ever-growing importance of the Chinese market and the increasing presence of Chinese players in the global medtech arena has not gone amiss in 2017, and the new year began with a flurry of announcements of further East-West partnerships being forged, including one by next-gen sequencing leader Illumina and by cancer therapy specialist Varian Medical Systems. Additionally, global investment firm Ally Bridge sealed a deal with LifeTech to co-invest in medtech companies looking to tackle China.